| Entry |
|
|---|
| Name |
Etanercept (USAN/INN);
Etanercept (genetical recombination) (JAN);
Etanercept (genetical recombination) [Etanercept biosimilar 1] (JAN);
Etanercept (genetical recombination) [Etanercept biosimilar 2] (JAN);
Enbrel (TN) |
|---|
| Product |
|
|---|
| Sequence |
LPAQVAFTPY APEPGSTCRL REYYDQTAQM CCSKCSPGQH AKVFCTKTSD TVCDSCEDST
YTQLWNWVPE CLSCGSRCSS DQVETQACTR EQNRICTCRP GWYCALSKQE GCRLCAPLRK
CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS
TSPTRSMAPG AVHLPQPVST RSQHTQPTPE PSTAPSTSFL LPMGPSPPAE GSTGDEPKSC
DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD
GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK |
|---|
| Type |
Peptide |
|---|
| Class |
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
|
|---|
| Remark |
| Therapeutic category: | 3999 |
|
|---|
| Efficacy |
Antirheumatic, TNF receptor antagonist |
|---|
| Disease |
Rheumatoid arthritis [DS: H00630] Polyarticular juvenile idiopathic arthritis [DS: H01672] Psoriatic arthritis [DS: H01507] Ankylosing spondylitis [DS: H01674] Plaque psoriasis [DS: H01656] |
|---|
| Comment |
recombinant fusion protein
To decrease signs and symptoms of rheumatoid arthritis
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04612 | Antigen processing and presentation |
| hsa04920 | Adipocytokine signaling pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07050 | Antirheumatics - DMARDs and biological agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
L04AB01 Etanercept
D00742 Etanercept (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunosuppressants
Tumor Necrosis Factor (TNF) Blockers
Etanercept
D00742 Etanercept (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D00742 Etanercept (USAN/INN); Etanercept (genetical recombination) (JAN); Etanercept (genetical recombination) [Etanercept biosimilar 1] (JAN); Etanercept (genetical recombination) [Etanercept biosimilar 2] (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
D00742 Etanercept
Drug classes [BR:br08332]
Immunological agent
DG01936 TNF inhibitor
D00742 Etanercept
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D00742 Etanercept
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Tumor necrosis factors
TNF (TNFA, TNFSF2)
D00742 Etanercept (USAN/INN) <JP/US>
LTA (TNFB, TNFSF1)
D00742 Etanercept (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00742
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00742
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|